

# INOVIQ BOARD EXPANDED WITH APPOINTMENT OF DAVID WILLIAMS AS CHAIRMAN

- David Williams appointed Non-Executive Director and Chairman effective 29 November 2023
- Mr Williams succeeds Dr Geoff Cumming who transitions to Non-Executive Director

**Melbourne, Australia, 11 October 2023:** INOVIQ Limited (ASX:IIQ) is delighted to announce the appointment of David Williams as a Non-Executive Director and Chairman Elect effective from the AGM on 29th November 2023. David will succeed Dr Geoffrey Cumming who has held the role since the acquisition of Sienna Cancer Diagnostics in July 2020. Dr Cumming will continue to serve on the Board as a Non-Executive Director.

Dr Cumming said: *“We are extremely pleased David will be joining the INOVIQ Board as Chairman. His strategic skills, energy, financial market know-how and corporate experience will be invaluable as we enter the next stage of our journey. David has been a strong long-term supporter of INOVIQ being its second largest shareholder having first entered the register in 2019. David’s increased involvement in the Company comes at a pivotal time in INOVIQ’s development as we progress commercialisation of our exosome technologies, advance development of our SubB2M cancer diagnostics and otherwise execute our strategic vision.”*

Mr Williams said: *“I am excited by the opportunity to assist INOVIQ to move from Research and Development to bringing its exosome and precision diagnostic solutions into the hands of clinicians for patients. I am passionate about technologies that have a positive impact on the lives of patients. Even better if the technology can be a platform and building block for other technologies. INOVIQ has multiple synergistic technologies and a strong internal team with robust external collaborations. A focus on getting the technology to market quickly while developing the platform for other indications will reward shareholders.”*

## About David Williams B.Ec(Hons), M.Ec, FAICD

Mr Williams is an experienced Director and investment banker with a track record in business development as well as in mergers and acquisitions and capital raising. He has experience advising ASX-listed companies in the food, medical device and pharmaceutical sectors. Mr Williams is currently Chairman of PolyNovo (ASX:PNV), Chairman of RMA Global (ASX:RMY) and is Managing Director of corporate advisory firm Kidder Williams.

Mr Williams will receive Directors fees including superannuation of \$100,000 and 6.45 million IIQ share options. Shareholders will have the opportunity to formally ratify this appointment and the share option issue as part of the upcoming 2023 AGM. Further details of Mr Williams share option issue will be contained in INOVIQ’s AGM Notice of Meeting.

- ENDS -

*Authorised by the Company Secretary, Mark Edwards.*

## COMPANY CONTACTS

**Dr Leearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-Executive Chairman  
E [geoff.cumming@inoviq.com](mailto:geoff.cumming@inoviq.com)  
M +61 417 203 021

**Jane Lowe**  
IR Department  
E [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
M +61 411 117 774

## ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, visit [www.inoviq.com](http://www.inoviq.com).

## FORWARD LOOKING STATEMENTS

This announcement contains certain ‘forward-looking statements’ within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as ‘may’, ‘should’, ‘expect’, ‘anticipate’, ‘estimate’, ‘scheduled’ or ‘continue’ or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.